Much has been made of Pfizer reaching the extraordinary mark of $100 billion in revenues in 2022, in large part undoubtedly thanks to the Covid-19 pandemic and its famous Covid-19 "Vaccine." Indeed, Pfizer's year-end earnings report shows that Covid-19 vaccine sales alone account for nearly 38 percent of those $100 billion in revenues.
Applying this margin to Pfizer's $37.8 billion in 2022 Covid-19 vaccine revenues gives around $10.4 billion in profits.
Roughly $3 billion and 30 percent more than Pfizer.
BioNTech made €12.95 billion in profits on €17.3 billion in revenues for a whopping 75 percent profit margin! This as compared to Pfizer's "High 20s" on C-19 vaccine revenues and 34.6 percent on all revenues.
In 2021, the difference between the BioNTech and Pfizer hauls was even greater, largely due to substantial milestone payments that Pfizer owed BioNTech per the terms of the collaboration agreement.
For 2021 and 2022 combined, BioNTech made over $31 billion in Covid-19 vaccine profits on a 77 percent profit margin as compared to Pfizer's just over $20 billion on the estimated 27.5 percent profit margin.
BioNTech made 50 percent more profits on a nearly three times higher profit margin.
https://brownstone.org/articles/biontechs-30-billion-reasons/
No comments:
Post a Comment